Multiple STIs Could Be Detected with A Single Rapid Test
|
By LabMedica International staff writers Posted on 26 Apr 2016 |

Image: A disposable cartridge for testing for a sexually transmitted disease (Photo courtesy of Atlas Genetics).
One test that could detect four of the most common sexually transmitted infections (STIs) in 30 minutes and allow them to be rapidly treated is under development. A GBP150,000 grant has been awarded to develop the test that will detect STIs, including chlamydia and gonorrhea.
Testing kits have been sent out by the UK National Chlamydia Screening Program aimed at those aged under 25 who did not have symptoms but wished to know they are clear of the infection. Their samples were then sent away for testing and those who tested positive for Chlamydia were offered the opportunity to trial the new technology.
Chlamydia is the UK’s most common STI with about 100,000 cases diagnosed each year and people under 25 years old are most at risk. If untreated, it can have serious long-term health consequences, including infertility in women. In some areas, one in five people never get treatment for their infection and others wait a long time before coming back to a clinic.
The test is being developed by scientists at St George’s, University of London (UK) and Atlas Genetics (Trowbridge, UK). The STI multiplex combines tests for four major nucleic acid targets, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, without the need for microscopy. The test is run on the Atlas Genetics’ io system which is a fully automated solution, requiring minimal hands-on time. Following the addition of an unprocessed patient specimen on to the io Cartridge, the Cartridge is then inserted in to the io Reader.
Tariq Sadiq MD, chief investigator at St. George’s, leads the eSTI2 Consortium which has developed a new smartphone app which allows patients to access an electronic clinic, the eSexual Health Clinic, to get rapid online treatment for chlamydia infection once they were diagnosed. Using a secure National Health System (NHS) log in, the app included an online medical consultation, leading to an electronic prescription for antibiotics, which patients could collect at a high street pharmacy. The app also enabled the patients’ sexual partners to get treatment quickly and easily in the same way. A clinical helpline is available for patients who need advice or support.
Eventually the eSexual Health Clinic will link to a hand held diagnostic device for STIs is also being developed by the scientists. This will mean that a urine or swab sample from patients would not have to be sent away for analysis, but can be analyzed at home so patients would receive their results within half an hour and then get their care online without ever needing to see a doctor face to face or attend a clinic.
Related Links:
St George’s, University of London
Atlas Genetics
Testing kits have been sent out by the UK National Chlamydia Screening Program aimed at those aged under 25 who did not have symptoms but wished to know they are clear of the infection. Their samples were then sent away for testing and those who tested positive for Chlamydia were offered the opportunity to trial the new technology.
Chlamydia is the UK’s most common STI with about 100,000 cases diagnosed each year and people under 25 years old are most at risk. If untreated, it can have serious long-term health consequences, including infertility in women. In some areas, one in five people never get treatment for their infection and others wait a long time before coming back to a clinic.
The test is being developed by scientists at St George’s, University of London (UK) and Atlas Genetics (Trowbridge, UK). The STI multiplex combines tests for four major nucleic acid targets, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, without the need for microscopy. The test is run on the Atlas Genetics’ io system which is a fully automated solution, requiring minimal hands-on time. Following the addition of an unprocessed patient specimen on to the io Cartridge, the Cartridge is then inserted in to the io Reader.
Tariq Sadiq MD, chief investigator at St. George’s, leads the eSTI2 Consortium which has developed a new smartphone app which allows patients to access an electronic clinic, the eSexual Health Clinic, to get rapid online treatment for chlamydia infection once they were diagnosed. Using a secure National Health System (NHS) log in, the app included an online medical consultation, leading to an electronic prescription for antibiotics, which patients could collect at a high street pharmacy. The app also enabled the patients’ sexual partners to get treatment quickly and easily in the same way. A clinical helpline is available for patients who need advice or support.
Eventually the eSexual Health Clinic will link to a hand held diagnostic device for STIs is also being developed by the scientists. This will mean that a urine or swab sample from patients would not have to be sent away for analysis, but can be analyzed at home so patients would receive their results within half an hour and then get their care online without ever needing to see a doctor face to face or attend a clinic.
Related Links:
St George’s, University of London
Atlas Genetics
Latest Technology News
- Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
- Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
- New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
- ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
- Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
- New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
- Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
- Autonomous Robotic System Receives FDA Authorization for Blood Collection
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Channels
Clinical Chemistry
view channel
New One-Step Syphilis Test Could Enable Earlier Detection and Faster Treatment
Syphilis can be difficult to diagnose because its symptoms may resemble other diseases and appear and disappear without treatment. Undetected infection can continue causing harm, spread to partners and... Read more
Multimodal Clinical Data Models Predict Cachexia Risk Across Cancers
Cancer cachexia is a severe wasting syndrome that affects roughly half of patients with cancer and cannot be reversed simply by increasing food intake. It can reduce treatment tolerance, impair quality... Read moreMolecular Diagnostics
view channel
RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more
Modeling Study Shows Blood-Based CRC Screening Could Prevent More Deaths Than Stool Tests
Colorectal cancer (CRC) screening depends on patient participation and completion of follow-up colonoscopy after an abnormal noninvasive result. Access barriers can make both steps difficult, particularly... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read morePathology
view channel
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read more
Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
Digital pathology is reshaping how laboratories manage case review, image analysis, and collaboration. As diagnostic workflows become more complex, pathology teams need platforms that can support digital... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Expanded Partnership Scales AI-Powered Digital Pathology for Oncology
Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care
Tuberculosis remains a major global infectious disease challenge despite declining deaths. In 2024, an estimated 10.7 million people worldwide developed the disease and nearly 1.2 million died from it.... Read more







.jpg)